Answers are grounded in this paper and cite their sources.
We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB). This combination demonstrated activity against our patient's refractory HB that had been extensively treated with multiple prior chemotherapeutic regimens. The patient had stabilization of radiographic disease coupled with an 83% decrease in his alpha-fetoprotein level. Given the response in this setting and the paucity of other available options, consideration could be given to using this combination as therapy in patients with recurrent HB who have failed more traditional agents.
No takes yet. Share an insight, caveat, or question.
Marsh et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: